Softer US PPI Eases Hawkish Fed Fears—but Inflation Relief Has Limits
A softer US PPI reading eased hawkish Fed fears and supported risk appetite, but officials still see inflation above the 2% goal.
Goldman Sachs Seeks a Second Payday From Anthropic’s IPO
Goldman Sachs is reportedly pursuing both underwriting fees and wealth-management business tied to A…
Go Residential’s Lawsuit Adds Legal Overhang for H&R REIT Shareholders
Go Residential is suing H&R REIT after shareholders rejected its acquisition offer, adding uncertain…
Cohere’s Cubic Acquisition Puts AI Cyber Defense at the Center of Consolidation
Cohere’s acquisition of Cubic signals how AI companies are moving into cybersecurity as enterprise a…
Viking Therapeutics Shares Gain as Renewed Takeover Interest Reignites Biotech M&A Speculation
Viking Therapeutics shares gained after renewed takeover-interest reports, putting biotech M&A premi…
Norfolk Southern–Union Pacific Merger Spread Widens as CEO Remarks Raise Deal Concerns
The widening Norfolk Southern–Union Pacific deal spread puts completion risk back at the center of t…
US Producer Prices Rise 6.5% in October, Keeping Fed Policy in Focus
October producer prices were slightly softer than forecast, but elevated inflation keeps Federal Res…
UniFirst-Cintas Deal Spread Widens as FTC 'Last Rites' Report Raises Antitrust Risk
A reported FTC “last rites” meeting has widened the UniFirst-Cintas deal spread, signaling higher ma…
FTC Merger Challenge Puts $3.5 Billion Covetrus-MWI Deal Spread in Focus
A reported FTC lawsuit to block the $3.5 billion Covetrus-MWI deal puts antitrust risk and merger-ar…
Cisco Raises AI Infrastructure Stakes After Earnings Beat and Revenue-Doubling Forecast
Cisco beat quarterly earnings expectations and forecast that AI infrastructure revenue will double t…
Cerebras Surges 13% After Revenue Beat and Microsoft Cloud Partnership
Cerebras shares rose 13% after a quarterly revenue beat and a new Microsoft partnership expanded its…
Nvidia Shares Face New Pressure as Lutnick Agrees to Testify on China Chip Sales
Nvidia’s 5% drop puts political scrutiny, China sales uncertainty and leadership concerns at the cen…
IBM’s AuthMind Acquisition Extends Its Push Into Cybersecurity
IBM’s AuthMind acquisition reinforces its cybersecurity and hybrid-cloud strategy, while leaving inv…
Markets
- Hancock Whitney-Trustmark Deal Signals Fresh Wave of Regional Bank Consolidation
- Investcorp Credit Management BDC Surges More Than 50% on BCP Investment Merger Deal
- Installed Building Products’ $698 Million Old Dominion Deal Puts Sector Consolidation in Focus
- Sabre Shares Jump on Report of Potential Travelport Combination
Economy
- Half-Point Fed Hike Risk Raises Stakes for U.S. Stocks, Bonds and Housing
- Hot Inflation Data Sends Mortgage Rates Higher as Wall Street Rate-Cut Hopes Fade
- Retail Sales Growth Slows to Nearly One-Year Low as Consumer Strain Builds
- Reuters Poll Points to Another Fed Rate Hike as Inflation Risks Persist
Analysis
- Airbnb Shares Rise 5.64% as Golden Cross Signals Renewed Technical Momentum
- Donchian Channel Breakout: 10-Year ETF Backtest
- MACD vs Moving Average Crossover: 9-Year SPY, QQQ Test
- ADX Trend Strength: What 10 Years of ETF Data Show
Earnings
- Costco Announces Special Dividend as Shareholders Watch Holiday Payout
- JetBlue CEO Bets on Premium Strategy Despite Creditor Concerns
- Boeing’s 5% Workforce Cut Signals Slower Commercial-Airplane Recovery
- ConocoPhillips Raises Dividend After Earnings Beat as Oil Prices Support Results
Technology
- Chip Stocks Rally Despite Nvidia Scandal as Traders Test a Potential Market Bottom
- Meta Executive’s Move to Fireworks Highlights Intensifying AI Talent War
- Palo Alto Networks’ Reported $500 Million Clutch Talks Put AI Security M&A in Focus
- CrowdStrike’s $495 Million AI Security Bet Puts Autonomous Defense in Focus
IPO
- Anthropic IPO Filing Ignites Tech Rally While Founder Control Tests Investors
- TriGemX Bio’s $600 Million SPAC Merger Creates a New Nasdaq Biotech Watchlist Name
- XTEND AI Robotics: Analyzing the Market Implications of Its NYSE Debut
- Werewolf Therapeutics and Ambros' Merger: A New Era in Biotech